Lackland Air Force Base

This research aims to compare the safety and effectiveness of Nanodropper-mediated microdrops versus standard eye drops in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHTN). The study hypothesizes that using Nanodropper, which delivers a smaller eye drop volume, will not significantly change intraocular pressure (IOP) compared to regular drops after daily use for three months. It also seeks to understand differences in side effects and usability between the two delivery methods. Participants will receive two types of treatments: standard eye drops delivering the full medication volume and Nanodropper microdrops delivering one-fifth of the regular volume. This randomized, single-masked, crossover trial involves each participant using both delivery systems. The study takes place at Wilford Hall Ambulatory Surgical Center and includes surveys at enrollment and follow-up visits to assess side effects and ease of use. During the study, researchers will monitor changes in mean intraocular pressure from baseline to six months. Participants will complete surveys to evaluate safety and usability. The trial focuses on measuring eye pressure to assess treatment effectiveness while tracking any side effects and participant feedback. The total participation period includes follow-up visits to collect data and monitor outcomes.